---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-039211"
form_type: "8-K"
ticker: "SCLX"
cik: "0001820190"
company_name: "Scilex Holding Co"
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:25:44.975912+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Scilex licenses ZTlido and SP-103 to RoyaltyVest for ex-US markets; 50% net revenue share

## Summary
- Licensed ZTlido (lidocaine topical system 1.8%) and SP-103 for commercialization outside US; Licensor retains US and stated territories.
- RoyaltyVest pays Scilex Pharma 50% of net revenue from ex-US sales; annual $200K commitment until first regulatory approval.
- Licensee must use commercially reasonable efforts to obtain regulatory approval in at least one Major Market Country within 18 months.
- Scilex Pharma grants exclusive, non-transferable license; Scilex Holding Company provides parent guarantee for performance.
- Agreement effective February 22, 2025, replacing the October 2024 Rest of World License Term Sheet.

## SEC filing metadata
- accession: 0001193125-25-039211
- form_type: 8-K
- ticker: SCLX
- cik: 0001820190
- company_name: Scilex Holding Co
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1820190/000119312525039211/0001193125-25-039211-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1820190/000119312525039211/d859484d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-039211
- JSON: https://secwatch.observer/filing/0001193125-25-039211.json
- Plain text: https://secwatch.observer/filing/0001193125-25-039211.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.